TUMOR-ASSOCIATED TRYPSIN-INHIBITOR (TATI) IN BENIGN AND MALIGNANT GASTRIC DISEASE

被引:4
|
作者
TORICAGUENA, AL
VALLEJO, AL
MERRUURRUTIA, MJD
ESCUDERO, JFL
机构
[1] Cruces' Hospital, Baracaldo (Vizcaya)
来源
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION | 1991年 / 51卷
关键词
TUMOR-ASSOCIATED TRYPSIN INHIBITOR; GASTRIC CANCER; TUMOR MARKERS; TUMOR STAGING;
D O I
10.3109/00365519109104629
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We have evaluated the clinical utility of tumor-associated trypsin inhibitor (TATI) as a marker for gastric cancer. For comparison we also studied CEA, CA19-9, CA-50 and TPA. The study comprised 93 patients with cancer and 45 with gastroduodenal ulcers. In 95% of the patients with benign disease the serum TATI concentrations were below 30-mu-g/l. Using this concentration as cut-off level 46% of the cancer patients had elevated levels. These were most common in advanced disease (68% in stage IVB) and patients with anaplastic tumors. Therefore TATI was a useful complement to CEA, which was most often elevated in patients with differentiated tumors. Addition of TATI to the battery of other markers increased the overall sensitivity for cancer from 69% to 80%.
引用
收藏
页码:59 / 62
页数:4
相关论文
共 50 条
  • [41] REACTION OF A TUMOR-ASSOCIATED TRYPSIN-INHIBITOR WITH SERINE PROTEINASES ASSOCIATED WITH COAGULATION AND TUMOR INVASION
    TURPEINEN, U
    KOIVUNEN, E
    STENMAN, UH
    BIOCHEMICAL JOURNAL, 1988, 254 (03) : 911 - 914
  • [42] TUMOR-ASSOCIATED TRYPSIN-INHIBITOR (TATI) - COMPARISON WITH CA125 AS A PREOPERATIVE PROGNOSTIC INDICATOR IN ADVANCED OVARIAN-CANCER
    VENESMAA, P
    LEHTOVIRTA, P
    STENMAN, UH
    LEMINEN, A
    FORSS, M
    YLIKORKALA, O
    BRITISH JOURNAL OF CANCER, 1994, 70 (06) : 1188 - 1190
  • [43] COMPARISON OF TUMOR-ASSOCIATED TRYPSIN-INHIBITOR (TATI) WITH CA125 AS A MARKER FOR DIAGNOSIS AND MONITORING OF EPITHELIAL OVARIAN-CANCER
    GADDUCCI, A
    FERDEGHINI, M
    RISPOLI, G
    PRONTERA, C
    BIANCHI, R
    FIORETTI, P
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1991, 51 : 19 - 24
  • [44] USE OF HCG, FREE BETA SUBUNIT AND TUMOR ASSOCIATED TRYPSIN-INHIBITOR (TATI) FOR MONITORING OF CHORIOCARCINOMA
    STENMAN, UH
    ALFTHAN, H
    HUHTALA, ML
    HALILA, H
    FRASER, R
    SCHRODER, J
    TUMOUR BIOLOGY, 1985, 6 (04): : 379 - 379
  • [45] HIGH-CONCENTRATIONS OF TUMOR-ASSOCIATED TRYPSIN-INHIBITOR IN HEMODIALYZED PATIENTS
    BANFI, G
    MURONE, M
    SLAVIERO, G
    CLINICAL CHEMISTRY, 1988, 34 (01) : 174 - 175
  • [46] TUMOR-ASSOCIATED TRYPSIN-INHIBITOR AND CANCER ANTIGEN 125 IN PELVIC MASSES
    MOGENSEN, O
    MOGENSEN, B
    JAKOBSEN, A
    GYNECOLOGIC ONCOLOGY, 1990, 38 (02) : 170 - 174
  • [47] TUMOR-ASSOCIATED TRYPSIN-INHIBITOR AS A POSSIBLE MARKER IN MALE-INFERTILITY
    BANFI, G
    MURONE, M
    VIGANO, P
    BRIGANTE, C
    BONINI, PA
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1991, 51 : 51 - 53
  • [48] TUMOR-ASSOCIATED TRYPSIN-INHIBITOR (TATI) IN PATIENTS WITH COLORECTAL-CANCER - A COMPARISON WITH CEA, CA-50 AND CA-242
    PASANEN, P
    ESKELINEN, M
    KULJU, A
    PENTTILLA, I
    JANATUINEN, E
    ALHAVA, E
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1995, 55 (02): : 119 - 124
  • [49] Tumor-associated trypsin inhibitor
    Stenman, UH
    CLINICAL CHEMISTRY, 2002, 48 (08) : 1206 - 1209
  • [50] Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder
    Shariat, SF
    Herman, M
    Casella, R
    Lotan, Y
    Karam, J
    Stenman, UH
    JOURNAL OF UROLOGY, 2005, 173 (04): : 229 - 230